Liposomes: A Highly Efficient and Reliable Nanocarrier For The Treatment Of Breast Cancer And Lung Cancer

Haoran Fei

doi:10.54097/jvw1cw28

Authors

Haoran Fei

DOI:

https://doi.org/10.54097/jvw1cw28

Keywords:

Liposomes; Breast cancer; Lung cancer; Nanocarrier.

Abstract

Cancer is one of the diseases with the highest mortality rates in the world today, and cancer itself is very difficult to treat. Among these, breast cancer and lung cancer are exceptionally severe types of cancer. The complexity, heterogeneity, drug resistance, and immune evasion of cancer present enormous challenges for doctors and scientists. In recent decades, scientists have explored various methods to tackle cancer. Although progress has been made, treating cancer remains challenging. Using nanocarriers to deliver drugs for targeted therapy is an effective treatment method. However, nanoparticle-based drug therapies encounter issues such as targeting selectivity, biocompatibility, and safety concerns. Liposomes, a type of nanocarriers encased in lipid bilayers that encapsulate pharmaceuticals, exhibit their advantages among a plethora of carriers. Liposomes possess characteristics such as multiple targeting capabilities, high bioavailability, and elevated safety. At present, it has emerged as a nanocarrier for combating various cancers, including breast cancer and lung cancer. This article will focus on the characteristics of liposomes and their therapeutic efficacy in the treatment of lung cancer and breast cancer.

Downloads

Download data is not yet available.

References

[1] Roy, P. S., & Saikia, B. J. Cancer and cure: A critical analysis. Indian journal of cancer, 2016, 53(3), 441–442.

[2] Reeves, G. K., Beral, V., Green, J., Gathani, T., Bull, D., & Million Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. The Lancet. Oncology, 2006, 7(11), 910–918.

[3] Cuzick, J., DeCensi, A., Arun, B., Brown, P. H., Castiglione, M., Dunn, B., Forbes, J. F., Glaus, A., Howell, A., von Minckwitz, G., Vogel, V., & Zwierzina, H. Preventive therapy for breast cancer: a consensus statement. The Lancet. Oncology, 2016, 12(5), 496–503.

[4] Almeida, B., Nag, O. K., Rogers, K. E., & Delehanty, J. B. Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery. Molecules (Basel, Switzerland), 2020, 25(23), 5672.

[5] Yang, B., Song, B. P., Shankar, S., Guller, A., & Deng, W. Recent advances in liposome formulations for breast cancer therapeutics. Cellular and molecular life sciences, CMLS, 2021, 78(13), 5225–5243.

[6] Candiani, G., Pezzoli, D., Ciani, L., Chiesa, R., & Ristori, S. Bioreducible liposomes for gene delivery: from the formulation to the mechanism of action. PloS one, 2010, 5(10), e13430.

[7] Fan, Y., Marioli, M., & Zhang, K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. Journal of pharmaceutical and biomedical analysis, 2021, 192, 113642.

[8] Zhang, W., Gong, C., Chen, Z., Li, M., Li, Y., & Gao, J. Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer. Journal of nanobiotechnology, 2021, 19(1), 339.

[9] Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. Breast cancer: Biology, biomarkers, and treatments. International immunopharmacology, 2020, 84, 106535.

[10] Sharma, G., Anabousi, S., Ehrhardt, C., & Ravi Kumar, M. N. Liposomes as targeted drug delivery systems in the treatment of breast cancer. Journal of drug targeting, 2006, 14(5), 301–310.

[11] Porche D. J. Liposomal doxorubicin (Doxil). The Journal of the Association of Nurses in AIDS Care: JANAC, 1996, 7(2), 55–59.

[12] Wang, S., Zhou, Z., Hu, R., Dong, M., Zhou, X., Ren, S., Zhang, Y., Chen, C., Huang, R., Zhu, M., Xie, W., Han, L., Shen, J., & Xie, C. Metabolic Intervention Liposome Boosted Lung Cancer Radio-Immunotherapy via Hypoxia Amelioration and PD-L1 Restraint. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023, 10(18), e2207608.

[13] Ruttala, H. B., & Ko, Y. T. Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy. Pharmaceutical research, 2015, 32(3), 1002–1016.

[14] Liu, P., Chen, G., & Zhang, J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules (Basel, Switzerland), 2022, 27(4), 1372.